Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report

Abstract

SMARCA4-deficient non small cell lung cancer (SMARCA4-dNSCLC) has recently garnered increasing attention due to its high malignancy and poor prognosis. The literature suggests that in non small cell lung cancer (NSCLC), the loss of SMARCA4 frequently co-occurs with mutations in KRAS, KEAP1, and STK11 rather than in EGFR, ALK, and ROS1. Herein, we present the first documented case of SMARCA4-dNSCLC accompanied with rare mutations of EGFR exon 20 S768I and exon 18 G719X. The patient achieved partial response with afatinib for 17 months. Our case highlights the importance of EGFR mutations in the precision targeted treatment of SMARCA4-dNSCLC.

Keywords

SMARCA4-dNSCLC / rare EGFR mutations / targeted therapy / case report

References

[1] Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, Noguchi M, Papotti M, Rekhtman N, Scagliotti G, van Schil P, Sholl L, Yatabe Y, Yoshida A, Travis WD. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol 2022; 17(3): 362–387

[2] Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn Pathol 2021; 38(5): 83–89

[3] Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, Husain AN, Kadota K, Khoor A, Nicholson AG, Roggli V, Schmitt F, Tsao MS, Travis WD. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol 2022; 17(5): 608–622

[4] Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, Egger J, Concepcion CP, Paul S, Arcila ME, Daneshbod Y, Chang J, Sauter JL, Beras A, Ladanyi M, Jacks T, Rudin CM, Taylor BS, Donoghue MTA, Heller G, Hellmann MD, Rekhtman N, Riely GJ. The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin Cancer Res 2020; 26(21): 5701–5708

[5] Wang X, Haswell JR, Roberts CW. Molecular pathways: SWI/SNF(BAF) complexes are frequently mutated in cancer-mechanisms and potential therapeutic insights. Clin Cancer Res 2014; 20(1): 21–27

[6] Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn Pathol 2021; 38(5): 83–89

[7] Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. SMARCA4 and other switch/sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition. J Thorac Oncol 2021; 16(7): 1176–1187

[8] Shi M, Pang L, Zhou H, Mo S, Sheng J, Zhang Y, Liu J, Sun D, Gong L, Wang J, Zhuang W, Huang Y, Chen Z, Zhao Y, Li J, Huang Y, Yang Y, Fang W, Zhang L. Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods. Lung Cancer 2024; 192: 107818

[9] Sheng J, Han W, Pan H. Thoracic SMARCA4-deficient undifferentiated tumor with ALK fusion treated with alectinib achieved remarkable tumor regression: case report. JTO Clin Res Rep 2023; 4(4): 100476

[10] Sun L, Fu Q, Chen L, Di M, Cao J. SMARCA4-deficient non-small cell lung cancer with an EGFR mutation: a case report. Oncol Lett 2023; 26(6): 513

RIGHTS & PERMISSIONS

Higher Education Press